Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial

This analysis of data from the placebo-controlled ODYSSEY OUTCOMES trial of alirocumab added to statin therapy in patients with recent ACS found achievement of LDL-C levels <0.65 mmol/L was associated with similar reduction in MACE to levels of 0.65-1.3 mmol/L.

Source:

Circulation